SCHAUMBURG, Illinois — Injectable drug manufacturer Sagent Pharmaceuticals closed its second $30 million Series A extension this week to help launch new products and other activities, the company stated.
Sagent originally raised $53 million in its first round in September 2007 and followed a year later with a $30 million extension. Vivo Ventures has lead each portion of this first-round fund raise.
The company has nine injectables for cardiovascular and anti-bacterial treatments in the market, six of which were launched in 2008. It launched an injectable Cefazolin, an antibiotic to treat infections, in February.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Sagent stated in its most recent release that it expects to have 20 products launched by year’s end.
